Key Stats for Boston Scientific Stock
- Price change for Boston Scientific stock: -9%
- $BSX Stock Price as of Mar. 30: $63
- 52-Week High: $110
- $BSX Stock Price Target: $102
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Boston Scientific (BSX) stock dropped after Raymond James downgraded the stock from Strong Buy to Outperform and cut its price target from $97 to $88.
The firm’s concern centers on two of the company’s biggest growth drivers: U.S. electrophysiology (EP) and its WATCHMAN device.
Raymond James now expects growth in both areas to be slower than previously forecast, with its new estimates just below the Wall Street consensus.
That said, the firm was careful to note this isn’t a loss of faith in the business.
Raymond James still views Boston Scientific as one of the highest-quality and fastest-growing companies in large-cap medical technology.
The downgrade was more about acknowledging that near-term outcomes are harder to predict than before, which lowers conviction in the rating.
The stock had already been sliding before today. Boston Scientific stock is down 34% year-to-date and trading near its 52-week low.
Raymond James acknowledged this, saying the weakness already reflects most of the growth concerns, which is why the firm stayed positive rather than going neutral.
The business itself is still performing well.
- Boston Scientific posted nearly 20% revenue growth over the past twelve months.
- In its most recent earnings call, management guided to 10%-11% organic revenue growth in 2026 and double-digit EPS growth.
- The WATCHMAN device grew 29% in Q4, and the EP business grew 35% for the full year.
See analysts’ growth forecasts and price targets for Boston Scientific stock (It’s free) >>>
What the Market Is Telling Us About Boston Scientific Stock
CHAMPION-AF trial for the WATCHMAN device was declared on 28 March 2026, and it was potentially positive. Raymond James called this a potential positive, and several other analysts agree.
Bernstein, Evercore ISI, Stifel, Truist, and Jefferies all maintain Buy or Outperform ratings, with price targets ranging from $88 to $120.
Boston Scientific stock is under pressure, but the story here is more about a valuation reset than a broken business.
The fundamentals are intact, and a strong CHAMPION readout could quickly imply a shift in sentiment.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Boston Scientific Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
